Gerresheimer manufactures insulin pen for sanofi-aventis

Date: 14 April 2011
Source: Gerresheimer AG
Gerresheimer AG has commenced the commercial production of ClikSTAR® insulin pens for sanofi- aventis.

Medical plastic systems such as insulin pens will be increasingly important in the Gerresheimer product portfolio in future because they incorporate a dosage and application function in addition to being a pure medication packaging.

The industrialisation of the insulin pen was prepared in Wackersdorf, the Gerresheimer Plastics Division’s technology center. Gerresheimer’s Pfreimd plant (Germany) is the place where the individual components are manufactured and assembled under clean room conditions.

“We are delighted about this sanofi-aventis production project because it involves a complex product that demonstrates our leadership in the medical plastic systems market to the pharma industry,” said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG. The re-usable ClikSTAR® insulin pen has received the Good Design Award.

Insulin pens are drug delivery systems in pen format that enable diabetes sufferers to reliably administer their regular insulin doses in a virtually pain-free procedure. Diabetes treatment is gaining in significance from year to year. According to World Health Organization (WHO) estimates, there will be around 350 million diabetes sufferers in the world by the year 2030.

ClikSTAR is a registered trademark of sanofi-aventis.

About Gerresheimer

Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.

Our Group realizes revenues of around one billion Euros and has 10,000 employees at 45 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.

600450 Gerresheimer manufactures insulin pen for sanofi-aventis

See more news about:

Others also read

Proprietary laminate windows collect, store energy; convert it to electricityRIVIERA BEACH, FL – An innovative new patented technology transforms office building windows into "solar farms" and allows these structures to reuse collected energy and become self-sufficient in the event of a power outage.
DALLAS, Texas, December 22, 2011 /PRNewswire/ --ReportsnReports adds new market research report 'Solar Photovoltaic (PV) Power - Global Market Size, Installation Prices, Module Market Shares, Market Segmentation, Regulations and Key Country Analysis to 2020' to its store.
The University of Minnesota's historic Folwell Hall completed three years of extensive renovation, just time for the 2011 academic year.
The renewal process for AAMA Corporate Members is now open. AAMA Corporate Membership is available to businesses involved in the manufacture, sale or service of fenestration products and is renewed on an annual basis.
Today designers and architects are looking to the hotel bathroom as the new frontier of the guestroom, turning what has long been a mostly functional space into a haven and means of escape.
Glassman as one of the largest glass processing machine manufactures in the world presented ZAK Glass Technology Exhibition during 8-11 December 2011, in Mumbai, India.

Add new comment